STOCK TITAN

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced it will report its first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. Following this, management will host a webcast at 8:00 a.m. ET to discuss the financial results and business progress. The event will be accessible through the investor section of the Esperion website, with a replay available approximately two hours later. Esperion is focused on developing innovative medicines for patients with cardiovascular and cardiometabolic diseases, particularly aiming to manage high cholesterol levels effectively.

Positive
  • Scheduled release of first quarter 2023 financial results, indicating ongoing business activities.
Negative
  • None.

ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023.

Following the release, company management will host a webcast at 8:00 a.m. ET to discuss financial results and business progress. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.

Already registered? Access with your PIN here. 

A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

ESPERION Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Contact:
Corporate Communications
corporateteam@esperion.com


FAQ

When will Esperion report its financial results for the first quarter of 2023?

Esperion will report its financial results on May 9, 2023.

What time is the webcast for Esperion's first quarter financial results?

The webcast will take place at 8:00 a.m. ET on May 9, 2023.

What is the focus of Esperion Therapeutics?

Esperion specializes in developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly for managing high cholesterol.

Where can I access the replay of Esperion's financial results webcast?

The replay will be available on Esperion's investor website approximately two hours after the live call.

Esperion Therapeutics, Inc.

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Stock Data

476.49M
196.07M
0.5%
66.33%
17.05%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR